MNOV - NASDAQ
MediciNova, Inc.
$1.32
-1.4%MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
At a Glance
Live SnapshotMediciNova, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
FCF Growth Trend
Steady FCF growth indicates consistent cash generation improvement. On a positive trajectory.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
MediciNova, Inc. Cash Flow Statement
MNOV • NASDAQ
| MediciNova, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||||||||
-12M | -11M | -8.6M | -14.1M | -10.1M | -13.9M | -12.9M | -14.7M | -11.2M | -10.9M | -8.8M | -9.2M | -4M | -11M | -17.7M | -20.2M | -20.4M | -21.9M | -48.9M | -35.7M | |
20.1K | 21.1K | 20.3K | 17.7K | 26.1K | 21.3K | 23.9K | 25.9K | 28.1K | 14.1K | 26.7K | 40.2K | 100.5K | 69.5K | 41.9K | 108.3K | 219.2K | 305K | 345.4K | -308.4K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -4M | 0.0 | -1.9M | -1.9K | 0.0 | -9.6K | -18.1K | 823.0 | 0.0 | 0.0 | -2B | 0.0 | 0.0 | -2.1B | |
829.1K | 1.2M | 710.7K | 642.5K | 1.7M | 3.2M | 4.1M | 6.3M | 4.5M | 4M | 2M | 1.6M | 1.2M | 709.7K | 1.4M | 2M | 2.4M | 3.2M | 0.0 | 2.1B | |
878.8K | 173.3K | 297.5K | 163.2K | 216.9K | 210.2K | 4M | -19.9K | 1.9M | 32.1K | 34.3K | -3.8K | -3.3K | -802.6K | 752.1K | 1.4M | 2B | 568.3K | 3.9M | 2.1M | |
(0.0) | (5K) | (3.7K) | (0.0) | (0.0) | (1.5K) | (11.3K) | (6K) | (9.2K) | (6K) | (7.4K) | (5.6K) | (6.4K) | (11K) | (12K) | (12.7K) | (9.4K) | (24.5K) | (0.0) | (0.0) | |
459.9K | -979.6K | 112K | 334.1K | -1.2M | -379.6K | -319.9K | -775.4K | -265.5K | 302.9K | -393.8K | 8.3M | -7.9M | -880.5K | 2.3M | -1M | 1.1M | -3.2M | 759.7K | -186.5K | |
-9.8M | -10.6M | -7.4M | -12.9M | -9.4M | -10.8M | -9.1M | -9.1M | -6.9M | -6.5M | -7.2M | 816.5K | -10.6M | -11.9M | -13.3M | -17.7M | -17M | -21.1M | -43.9M | -34.1M | |
INVESTING ACTIVITIES | ||||||||||||||||||||
(0.0) | -895.0 | -21.3K | -5K | -28.7K | -36.5K | -11.3K | -10.2K | (0.0) | -84.5K | -2.3K | -3.5K | -41.6K | -83.4K | -6.1K | -18.6K | -16.4K | (0.0) | -380.7K | -209K | |
(0.0) | (0.0) | (0.0) | (5M) | (0.0) | (0.0) | (0.0) | (636.5K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -680K | (0.0) | -458K | -2.4M | (0.0) | (0.0) | (243M) | |
(0.0) | (0.0) | (0.0) | -59.9M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (476.6M) | (2.4B) | -2M | -41.7M | -108.2M | |
0.0 | 0.0 | 39.9M | 19.9M | 0.0 | 0.0 | 0.0 | 636.5K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 28.1M | 1.3M | 23.6M | 85.7M | 114.2M | |
-2.9K | 198.0 | 0.0 | -5M | 0.0 | 0.0 | -11.3M | 636.5K | -84.5M | -84.5M | -2.3M | -3.5M | 4.8K | -680.0 | -6.1M | -476.6M | -2.4B | 24B | 62K | -243M | |
-2.9K | -697.0 | (39.9M) | -40M | -28.7K | -36.5K | -11.3K | (626.3K) | -84.5M | -84.5K | -2.3K | -3.5K | -36.8K | -763.4K | -6.1K | (27.6M) | -1.1M | (21.6M) | (43.6M) | (5.8M) | |
FINANCING ACTIVITIES | ||||||||||||||||||||
0.0 | 0.0 | 0.0 | 7.9K | 20.9M | 7.3M | 10.9M | 42.8M | 10.7M | 8.6M | 17.5M | 4.1M | 13.4M | 1.5M | 9.7M | 204.1K | 488.3K | 86.7K | 10.7M | -1.1M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -14.9M | -1.1M | 17.6M | 0.0 | 0.0 | 0.0 | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (8.2K) | (37.5K) | (0.0) | (0.0) | (0.0) | -1.4M | |
244K | 0.0 | 0.0 | 0.0 | -112.3K | -192.1K | 0.0 | 51K | 77.3K | 87.7K | 89.9K | 60.5K | 6.7K | 58.6K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
244K | 0.0 | 0.0 | 7.9K | 20.8M | 7.1M | 10.6M | 42.8M | 10.8M | 8.7M | 17.6M | 4.2M | 13.4M | 1.5M | 155.7K | -926.6K | 18.1M | 86.7K | 10.7M | -1.1M | |
CASH FLOW SUMMARY | ||||||||||||||||||||
15.7K | 4K | 17.3K | -16.8K | 26.5K | 1.2K | 0.0 | 691.0 | 614.0 | 6.3K | -1.7K | -6.3K | 2.5K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-9.6M | -10.6M | 32.5M | -52.9M | 11.4M | -3.8M | 1.5M | 34.3M | 3.9M | 2M | 10.4M | 5M | 2.7M | -11.1M | -13.2M | 9M | -55.7K | 518.3K | 10.4M | -29.3M | |
40.4M | 51M | 18.5M | 71.4M | 60M | 63.8M | 62.3M | 28M | 24.1M | 22.1M | 11.7M | 6.7M | 4M | 15.1M | 28.3M | 19.2M | 19.3M | 18.8M | 8.3M | 37.7M | |
30.8M | 40.4M | 51M | 18.5M | 71.4M | 60M | 63.8M | 62.3M | 28M | 24.1M | 22.1M | 11.7M | 6.7M | 4M | 15.1M | 28.3M | 19.2M | 19.3M | 18.8M | 8.3M | |
-9.8M | -10.6M | -7.5M | -12.9M | -9.4M | -10.9M | -9.1M | -9.1M | -6.9M | -6.6M | -7.2M | 813K | -10.7M | -11.9M | -13.3M | -17.7M | -17M | -21.1M | -44.2M | -34.3M |
SEC Filings
MNOV - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 14, 2026 | March 31, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 29, 2026 | June 23, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 10, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 20, 2026 | February 20, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 30, 2025 | December 29, 2025 | 2025 | |
S-3 S-3 N/A | December 05, 2025 | December 05, 2025 | ||
10-Q 10-Q 2025 Q3 Q3 | November 12, 2025 | September 30, 2025 | 2025 | |
S-1 S-1 N/A | August 22, 2025 | August 22, 2025 | ||
10-Q 10-Q 2025 Q2 Q2 | August 14, 2025 | June 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 01, 2025 | July 30, 2025 | 2025 |
Related Guides
Continue your MNOV research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.